Published in J Hepatol on December 01, 2004
Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol (2010) 1.14
Drug-Induced Liver Injury: Pattern Recognition and Future Directions. Gut Liver (2016) 0.84
Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. Int J Mol Sci (2016) 0.82
Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. Int J Mol Sci (2016) 0.81
Drug-induced Liver Injury. US Gastroenterol Hepatol Rev (2010) 0.76
Acute liver injury associated with a newer formulation of the herbal weight loss supplement Hydroxycut. BMJ Case Rep (2015) 0.76
Teratogenic Effect of Usnic Acid from Cladonia substellata Vainio during Organogenesis. Biomed Res Int (2017) 0.75
Inhibitory Activity of (+)-Usnic Acid against Non-Small Cell Lung Cancer Cell Motility. PLoS One (2016) 0.75
Herbal and Dietary Supplement-Induced Liver Injury. Clin Liver Dis (2016) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology (2006) 3.76
Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology (2006) 3.70
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology (2003) 3.18
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem (2008) 3.08
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology (2004) 2.26
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (2006) 2.12
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Drug-induced liver injury. Drug Saf (2007) 1.99
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol (2006) 1.89
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. Hepatology (2003) 1.72
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J Gastroenterol (2004) 1.68
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68
Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest Endosc (2010) 1.65
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Effect of glutathione depletion on sites and topology of superoxide and hydrogen peroxide production in mitochondria. Mol Pharmacol (2003) 1.62
Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol (2006) 1.62
Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.61
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol (2013) 1.61
ER stress: can the liver cope? J Hepatol (2006) 1.58
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Transplantation: impact of pretransplant renal insufficiency. Liver Transpl (2008) 1.58
c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem (2011) 1.57
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56
Glutathione in liver diseases and hepatotoxicity. Mol Aspects Med (2008) 1.55
Serum alanine aminotransferase in skeletal muscle diseases. Hepatology (2005) 1.54
Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol (2005) 1.54
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl (2013) 1.52
Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next? Hepatology (2004) 1.51
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology (2006) 1.50
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50
Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci (2007) 1.50
The contribution of endoplasmic reticulum stress to liver diseases. Hepatology (2011) 1.50
Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Role of CHOP in hepatic apoptosis in the murine model of intragastric ethanol feeding. Alcohol Clin Exp Res (2005) 1.49
Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr (2007) 1.49
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41
Immune-mediated drug-induced liver disease. Clin Liver Dis (2002) 1.38
Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transpl (2011) 1.37
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37
Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J Biol Chem (2010) 1.37
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology (2009) 1.35
Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol (2006) 1.35
Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis (2008) 1.33
Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology (2004) 1.31
A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation (2004) 1.30
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol (2007) 1.29
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology (2007) 1.27
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol (2008) 1.26
Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice. Hepatology (2011) 1.23
Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf (2013) 1.23
Access to liver transplantation in the MELD era: role of ethnicity and insurance. Dig Dis Sci (2008) 1.21
Allograft survival following adult-to-adult living donor liver transplantation. Am J Transplant (2004) 1.20
Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. J Biol Chem (2010) 1.20
Portal vein thrombosis: a concise review. Am J Gastroenterol (2002) 1.20
Current trends in living donor liver transplantation for primary sclerosing cholangitis. Transplantation (2011) 1.19
Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology (2003) 1.19
Primary hepatic non-Hodgkin's lymphomas: case report and review of the literature. Am J Gastroenterol (2003) 1.19
Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci (2012) 1.18